Skip to main content
Premium Trial:

Request an Annual Quote

Mitchell Fogelman, Carlo Croce

Premium
CytRx, the parent firm of RNAi drugs developer RXi Pharmaceuticals,has named Mitchell Fogelman as its new CFO.
 
Fogelman replaces Matthew Natalizio who CytRx said left to “pursue other opportunities.”
 
Fogelman has held positions with International Aluminum, an industrial products maker, and accounting firm PricewaterhouseCoopers.
 

He holds an MBA and BA from the University of California, Los Angeles.

 

 
Cepheid, a molecular diagnostics firm, has appointed Ohio State University professor and microRNA researcher Carlo Croce to its scientific advisory board.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.